Twitter Facebook LinkedIn
Center for Global Research Data

Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: A Post Hoc Analysis of a Randomized Controlled Trial

Lead Investigator: Matthew Gilbert, University of Vermont
Title of Proposal Research: Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: A Post Hoc Analysis of a Randomized Controlled Trial
Vivli Data Request: 5435
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

The complications of type 2 diabetes increase with age, making treatment of older persons a challenge. Clinical studies on the effect of diabetes treatments on cardiovascular events in older adults are limited. Glucagon-like peptide 1 agonists are among the newer classes of diabetes medications to treat type 2 diabetes. Some of the agents in this class of mediation have been shown to reduce the risk of cardiovascular death in patients with type 2 diabetes who already have cardiovascular disease. The purpose of our study is to see if this beneficial effect of this medication is seen in older adults with type 2 diabetes treated with albiglutide. A secondary analysis of data from the LEADER clinical trial evaluated whether age interacted with liraglutide for major cardiovascular outcomes (1). Although the age-treatment interaction was not statistically significant, a trend for greater efficacy was seen in the 75+ age group. We would like to replicate the same analyses using data from the NCT02465515 trial of diabetics aged >75 years and aged >65 to <75 years with established cardiovascular disease.

Requested Studies:

A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Sponsor: GlaxoSmithKline
Study ID: NCT02465515
Sponsor ID: GLP116174